Saturday, 08 August 2020


China vitamin C manufacturer fined by US court

20 March 2013 | News | By BioSpectrum Bureau

Weisheng Pharmaceutical and China Pharmaceutical settled the case out of court by offering to pay $22.5 million

Weisheng Pharmaceutical and China Pharmaceutical settled the case out of court by offering to pay $22.5 million

Singapore: A US court has fined North China Pharmaceutical (NCPC), a vitamin C manufacturer and antibiotics supplier, $162 million for price fixing. This is the first time that a Chinese drug company has been fined in an US anti-trust case.

Weisheng Pharmaceutical and China Pharmaceutical, also Vitamin C manufacturers from China and named in the lawsuit, have settled the case out of court by offering to pay $22.5 million. NCPC manufacturers over 430 kinds of antibiotics, semi-synthetic antibiotics, pharmaceutical intermediates, vitamins, biotechnology products, veterinary and neutraceuticals both in bulk and in finished products.

NCPC and Hebei Welcome Pharmaceutical, its Vitamin C production unit, were found guilty in a conspiracy to fix prices of Vitamin C' tablets in the US. The lawsuit were filed last month by two US companies. The NCPC reportedly said it would appeal the ruling.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account




Podcast

 

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls